Xylometazoline

Phase 3Completed
0 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Common Cold

Conditions

Common Cold

Trial Timeline

Mar 1, 2007 → Apr 1, 2007

About Xylometazoline

Xylometazoline is a phase 3 stage product being developed by Novartis for Common Cold. The current trial status is completed. This product is registered under clinical trial identifier NCT00452270. Target conditions include Common Cold.

What happened to similar drugs?

5 of 16 similar drugs in Common Cold were approved

Approved (5) Terminated (3) Active (9)

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00452270Phase 3Completed